MARKET

PRTA

PRTA

Prothena Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.32
-0.28
-1.24%
After Hours: 22.32 0 0.00% 16:58 02/26 EST
OPEN
23.85
PREV CLOSE
22.60
HIGH
24.74
LOW
22.26
VOLUME
451.91K
TURNOVER
--
52 WEEK HIGH
27.20
52 WEEK LOW
7.10
MARKET CAP
891.05M
P/E (TTM)
-8.0158
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insider at Prothena (PRTA) Makes Significant purchase of Stock Extends the Trend of Last Quarter
MT Newswires · 1d ago
10-K: PROTHENA CORP PUBLIC LTD CO
Edgar Online - (EDG = 10Q, 10K) · 2d ago
Premarket analyst action - healthcare
Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform
Seekingalpha · 2d ago
--Analyst Actions: RBC Upgrades Prothena to Outperform-Speculative Risk From Sector Perform, Adjusts Price Target to $28 From $14
MT Newswires · 2d ago
Chronic Traumatic Encephalopathy (CTE) Market Analysis, Growth, Opportunities, Inudstry Trends, Price and Report 2020-2027
Japan, Japan, Fri, 26 Feb 2021 01:28:09 / Comserve Inc. / -- Competitive Analysis: Eustralis Pharmaceuticals Ltd, Eli Lilly, Prothena Corp Plc, Amarantus...
Comserve · 3d ago
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
BERKELEY HEIGHTS, N.J., Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc....
GlobeNewswire · 3d ago
BRIEF-Prothena Reports Data From Its Neurodegenerative Programs Selected For Oral Presentations At AD/PD 2021
reuters.com · 4d ago
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of pra...
GlobeNewswire · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTA. Analyze the recent business situations of Prothena Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTA stock price target is 26.43 with a high estimate of 35.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 227
Institutional Holdings: 37.05M
% Owned: 92.81%
Shares Outstanding: 39.92M
TypeInstitutionsShares
Increased
24
1.25M
New
50
2.43M
Decreased
51
5.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
Gene Kinney
Chief Financial Officer/Chief Operating Officer
Tran Nguyen
Chief Accounting Officer/Controller
Karin Walker
Chief Scientific Officer
Wagner Zago
Other
Carol Karp
Other
Brandon Smith
Other
Radhika Tripuraneni
Secretary
Michael Malecek
Independent Director
Paula Cobb
Independent Director
Richard Collier
Independent Director
Shane Cooke
Independent Director
K. Anders Harfstrand
Independent Director
Christopher Henney
Independent Director
Oleg Nodelman
Independent Director
Dennis Selkoe
  • Dividends
  • Splits
  • Insider Activity
No Data
About PRTA
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.